Nova Retard: Bosentan
نویسندگان
چکیده
منابع مشابه
Bosentan monohydrate
In the title compound, C27H29N5O6S·H2O {systematic name: 4-tert-butyl-N-[6-(2-hy-droxy-eth-oxy)-5-(2-meth-oxy-phen-oxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide monohydrate], the dihedral angle between the mean planes of the pyrimidine rings is 27.0 (1)°. The dihedral angle between the mean planes of the benzene rings is 47.7 (8)°, forming a U-shaped channel around the chain of tw...
متن کاملMultidisciplinary Rehabilitation of the Mental Retard
The ligislation, social reforms and extensive research programmes hi the Twent ie th Century have benefitted the mentally retarded population. Prior to this, the mentally retarded were institutionalised and received only custodial care. As research progressed, the living conditions for the mentally retarded improved and the concept of the multifaceted approach to the problem of the mental retar...
متن کاملArtificial liver support: potential to retard regeneration?
HYPOTHESIS The concept of an "artificial liver" has been in development for over 40 years. Such devices aim to temporarily assume metabolic and excretory functions of the liver, with removal of potentially hepatotoxic substances, thereby clinically stabilizing patients and preventing deterioration while awaiting transplantation. If sufficient numbers of viable hepatocytes remain, regeneration a...
متن کاملQuark - Nova
We explore the scenario where the core of a neutron star (having experienced a transition to an up and down quark phase) shrinks into the equilibrated quark object after reaching strange quark matter saturation density (where a composition of up, down and strange quarks is the favored state of matter). The overlaying (envelope) material free-falls following the core contraction releasing upto 1...
متن کاملBosentan therapy for portopulmonary hypertension.
The dual endothelin receptor antagonist bosentan has been approved in several countries for pulmonary arterial hypertension, and patients with portopulmonary hypertension (PPHTN) have not specifically been excluded. However, no data have been published on the efficacy and safety of bosentan in this patient population. Here, the first clinical experiences with bosentan in patients with Child A c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Forum Médical Suisse ‒ Swiss Medical Forum
سال: 2011
ISSN: 1661-6146,1661-6138
DOI: 10.4414/fms.2011.07581